BeOne Medicines AG (ONC)

Market Cap	35.76B +52.8%
Revenue (ttm)	5.34B +40.2%
Net Income	286.93M
EPS	2.47
Shares Out	110.94M
PE Ratio	130.51
Forward PE	56.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	745,971
Open	328.62
Previous Close	352.23
Day's Range	315.50 - 334.05
52-Week Range	196.45 - 385.22
Beta	0.52
Analysts	Strong Buy
Price Target	370.25 (+14.85%)
Earnings Date	Feb 26, 2026

About ONC

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://beonemedicines.com

Analyst Summary

According to 12 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $370.25, which is an increase of 14.85% from the latest price.

Price Target

$370.25

(14.85% upside)

Analyst Consensus: Strong Buy